Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Thread Tools Display Modes
Old 05-20-2014, 11:03 AM   #1
Senior Member
'lizbeth's Avatar
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Clinical impact of differential risk stratification by breast cancer index (BCI) vers

I've edited slightly to make this more readable - 'lizbeth

Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR+ early-stage breast cancer: A TransATAC study.

Abstract No:
Attend this session at the
2014 ASCO Annual Meeting!

Session: Breast Cancer - HER2/ER
Type: Poster Highlights Session
Time 1: Sunday June 1, 8:00 AM to 11:00 AM
Location 1: E354b

Time 2: Sunday June 1, 11:30 AM to 12:45 PM
Location 2: E Arie Crown Theater
Personalize your Meeting experience with a suggested or customized itinerary!

Author(s): Ivana Sestak, Yi Zhang, Catherine A. Schnabel, Brock Schroeder, Mark Erlander, Paul E. Goss, Jack M. Cuzick, Mitchell Dowsett, Dennis Sgroi; Queen Mary, University of London, London, United Kingdom; bioTheranostics, Inc., San Diego, CA; Trovagene, San Diego, CA; Massachusetts General Hospital Cancer Center, Boston, MA; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Massachusetts General Hospital, The Avon Foundation, Boston, MA
Abstract Disclosures


Background: Breast cancer index (BCI) is a genomic signature that significantly predicts risk of both early (0-5y) and late (5-10y) distant recurrence (DR) in HR+, LN- breast cancer. Previous results from the TransATAC study showed that both breast cancer index (BCI) and Oncotype Dx RS added significant prognostic information for 10y DR risk. Here, pre-defined risk stratification with breast cancer index (BCI) vs recurrence score (RS) and its potential clinical impact were comparatively evaluated. Methods: 665 HR+, LN- patients were examined. BCI and recurrence score (RS) risk groups were determined using pre-defined clinical cut-points. Kaplan-Meier estimates of 10y risk of DR and log-rank tests were used to examine cross-stratification between breast cancer index (BCI) and recurrence score (RS). Likelihood Ratio (LR) tests were used to quantitate relative prognostic information beyond CTS. Results: breast cancer index (BCI) re-stratification of the RS-Intermediate (RS-I) and RS-Low (RS-L) groups significantly impacted risk of 10y DR (P=0.003 and P<0.001), whereas RS did not significantly re-stratify BCI risk prediction (Table). breast cancer index (BCI) identified a small subset (20 pts in RS-L) with a high risk of DR (23.3%). Furthermore, breast cancer index (BCI) identified a large (95 pts in RS-I) and smaller (34 pts in RS-I) subset with 7.1% and 27.8% 10y DR risk, respectively. BCI added significant prognostic information beyond CTS+ RS (p=0.0009), whereas recurrence score (RS) did not provide additional prognostic information beyond CTS+ breast cancer index (BCI) (p=0.1). Conclusions: In this retrospective analysis evaluating individualized risk stratification, breast cancer index (BCI) identified subsets of RS-L and RS-I LN- patients with significant and clinically distinct rates of DR. Breast cancer index (BCI) identified a small subset of RS-L and RS-I LN- patients that would potentially benefit from additional therapy.

Risk stratification and 10-year distant recurrence rates (%).
No. of patients
BCI risk groups
Low Inter High Total P value
RS risk groups Low 283

Inter 95

High 12

Total 390

P value 0.4 0.07 0.6
'lizbeth is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 04:52 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter